Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants (Fase1B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01081847
Recruitment Status : Completed
First Posted : March 5, 2010
Last Update Posted : March 8, 2010
Centro médico Imbanaco
Asoclinic Inmunología Ltda.
Information provided by:
Malaria Vaccine and Drug Development Center

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : March 2006
  Study Completion Date : April 2006